#	Pagina
attuale pagina	/open-h2020/projects/198097/index.html

Opendata, web and dolomites

IMMPACT

Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

IMMPACT project word cloud

Explore the words cloud of the IMMPACT project. It provides you a very rough idea of what is the project "IMMPACT" about.

pancreatologists pancreatic diagnose signature yes serum ab immpact trials immunovia stems implication blood individuals population validating groups initial strategy dimension antibody exploits laying risk stage detection once opportunity accelerate business proteomics asymptomatic tests retrospective lies separate basis patients first extensive world screening resectable international platform recombinant perform hence microarray time validation validated underlying network healthy detected confirmed affinity cancer primarily prospective unmet benefit efforts pdac undertaken diagnosis aligned patient tremendous indicate accurately owned biomarker body clinical

Project "IMMPACT" data sheet

The following table provides information about the project.

Coordinator	IMMUNOVIA AB Organization address address: SCHEELEVAGEN 2 MEDICON VILLAGE city: LUND postcode: 223 81 website: www.immunovia.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://immunovia.com/
Total cost	4˙244˙969 €
EC max contribution	4˙244˙969 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2018-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	IMMUNOVIA AB IMMUNOVIA AB Organization address address: SCHEELEVAGEN 2 MEDICON VILLAGE city: LUND postcode: 223 81 website: www.immunovia.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	coordinator	4˙244˙969.00

Map

Project objective

The IMMPACT project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice. The European dimension of the project lies in the validation of the biomarker signature that will make it possible for the first time to accurately diagnose pancreatic cancer in an asymptomatic stage (I and II) when the cancer is resectable. The results of the project will help to build up evidence that pancreatic cancer can be detected at an early stage, thus laying the basis for the future implementation of screening programmes of population groups at risk. The project stems from the unmet clinical need for the early detection of PDAC. Pancreatologists need a reliable biomarker for the early diagnosis (yes/no) diagnosis of pancreatic cancer. The test should primarily indicate whether the patient has cancer, not if the patient has a high risk of getting cancer. The new biomarker signature will address those needs and allow Immunovia to benefit from the tremendous business opportunity. Immunovia’s business strategy is based on extensive efforts towards validating the new biomarker signature by retrospective and prospective clinical trials. The validation to be undertaken in the project will accelerate an international clinical uptake of Immunovia’s blood based-tests. The project is thus fully aligned with Immunovia’s business development strategy.

Deliverables

List of deliverables.
Project website	Websites, patent fillings, videos etc.	2019-07-25 13:44:24
Retrospective clinical study report Herlev Study	Documents, reports	2019-07-25 13:44:24
Retrospective clinical study report OHSU Study	Documents, reports	2019-07-25 13:44:24
Simplified user interface	Other	2019-07-25 13:44:24
Retrospective clinical study report PANCAN Study	Documents, reports	2019-07-25 13:44:23
Retrospective clinical study report OXFORD Study	Documents, reports	2019-07-25 13:44:23
Interim prospective validation report	Documents, reports	2019-07-25 13:44:23

Take a look to the deliverables list in detail: detailed list of IMMPACT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMPACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMPACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials